Remedy Robotics Raises $62 Million for N1 Development
Remedy Robotics raised $62 million to advance its N1 endovascular robotics platform, fund a pivotal University of California trial and pursue FDA approval.
By Amara Osei
3 min read

By Amara Osei
Remedy Robotics raised $62 million in a Series B funding round to advance its AI-enabled endovascular robotic platform toward clinical trials and potential regulatory approval. Remedy Robotics said DCVC led the round, joined by UC Investments, Skip Capital and Hostplus. Existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated, according to the company.
What does the $62 million fund?
Remedy Robotics said the financing supports a planned pivotal trial with the University of California and development toward FDA approval for neurovascular intervention. Remedy also plans prototype deployments across its clinical partner network, including work with SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Jake Sganga, Chief Technology Officer And Co-Founder Of Remedy Robotics, said:
“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy.
We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”
How does the N1 System work?
Remedy Robotics said the N1 System combines robotics, machine learning and computer vision. The system is designed to analyze preoperative images, simulate procedures and register three-dimensional images against two-dimensional images during intervention.
It is being designed for on-site, remote and potentially autonomous operation. Remedy Robotics said it continues developing the system’s AI and autonomous functions.
How far along is the platform?
Remedy Robotics said it works with more than 100 hospitals worldwide. In October 2025, the company announced the completion of remote neurointerventional procedures using the N1 System.
The company said the system remains under development and is not currently available for sale or clinical use in any jurisdiction. Remedy Robotics also said its clinical and research work has appeared in peer-reviewed neuroradiology journals.
Remedy Robotics said it holds 48 patents covering the platform, including machine learning applications in surgical robotics. The San Francisco-based company has worked with University of California clinical specialists since 2021.
Why does specialist access matter?
Remedy Robotics set out to address limited access to specialists who perform endovascular procedures. The company said distance from a treatment center can delay emergency care.
Dr. David Bell, CEO And Co-Founder Of Remedy Robotics, said:
“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating.
Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common. This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.”
What do investors expect?
James Hardiman, General Partner At DCVC, said:
“Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges. We believe the company is uniquely positioned to redefine how life-saving intervention is delivered and are thrilled to support them as they advance toward broader clinical and commercial adoption.”
Michael Tolo, Partner At Blackbird, said:
“Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category. We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth.”
What gates commercial deployment?
Remedy Robotics said the new capital supports the next stage of testing and development. Commercial deployment depends on clinical results, regulatory progress and completion of the system.
The planned University of California pivotal trial, prototype deployments and FDA work are the next milestones. Remedy Robotics said commercial deployment depends on clinical results, regulatory progress and completion of the system.
Source: pulse2.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,136 articles